4.92 USD
-0.16 (-3.15%)
4.92 USD
0 (0%)
We assign a fundamental rating of 2 out of 10 to EOLS. EOLS was compared to 190 industry peers in the Pharmaceuticals industry. EOLS has a bad profitability rating. Also its financial health evaluation is rather negative. EOLS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- EOLS had negative earnings in the past year.
- In the past year EOLS has reported a negative cash flow from operations.
- In the past 5 years EOLS always reported negative net income.
- EOLS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- EOLS has a Return On Assets (-26.74%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -26.74% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-32.04%
ROA(5y)-38.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Gross Margin, with a value of 65.83%, EOLS is in the better half of the industry, outperforming 74.87% of the companies in the same industry.
- In the last couple of years the Gross Margin of EOLS has declined.
- EOLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 65.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.76%
GM growth 5Y-2.34%
2. Health
2.1 Basic Checks
- EOLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for EOLS has been increased compared to 1 year ago.
- EOLS has more shares outstanding than it did 5 years ago.
- EOLS has a better debt/assets ratio than last year.
2.2 Solvency
- EOLS has an Altman-Z score of -2.35. This is a bad value and indicates that EOLS is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -2.35, EOLS is in line with its industry, outperforming 40.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.35 |
ROIC/WACCN/A
WACC11.07%
2.3 Liquidity
- EOLS has a Current Ratio of 2.02. This indicates that EOLS is financially healthy and has no problem in meeting its short term obligations.
- EOLS has a worse Current ratio (2.02) than 61.26% of its industry peers.
- A Quick Ratio of 1.53 indicates that EOLS should not have too much problems paying its short term obligations.
- With a Quick ratio value of 1.53, EOLS is not doing good in the industry: 61.78% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.02 | ||
| Quick Ratio | 1.53 |
3. Growth
3.1 Past
- EOLS shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.76%.
- EOLS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.10%.
- Measured over the past years, EOLS shows a very strong growth in Revenue. The Revenue has been growing by 50.14% on average per year.
EPS 1Y (TTM)-9.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.25%
Revenue 1Y (TTM)15.1%
Revenue growth 3Y38.74%
Revenue growth 5Y50.14%
Sales Q2Q%12.9%
3.2 Future
- EOLS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 68.91% yearly.
- Based on estimates for the next years, EOLS will show a very strong growth in Revenue. The Revenue will grow by 20.36% on average per year.
EPS Next Y-81.56%
EPS Next 2Y56.23%
EPS Next 3Y65.85%
EPS Next 5Y68.91%
Revenue Next Year11.72%
Revenue Next 2Y13.12%
Revenue Next 3Y16.42%
Revenue Next 5Y20.36%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for EOLS. In the last year negative earnings were reported.
- With a Price/Forward Earnings ratio of 44.66, EOLS can be considered very expensive at the moment.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of EOLS indicates a somewhat cheap valuation: EOLS is cheaper than 69.63% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 25.98, EOLS is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 44.66 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- EOLS's earnings are expected to grow with 65.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y56.23%
EPS Next 3Y65.85%
5. Dividend
5.1 Amount
- No dividends for EOLS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
EVOLUS INC / EOLS FAQ
What is the ChartMill fundamental rating of EVOLUS INC (EOLS) stock?
ChartMill assigns a fundamental rating of 2 / 10 to EOLS.
What is the valuation status of EVOLUS INC (EOLS) stock?
ChartMill assigns a valuation rating of 2 / 10 to EVOLUS INC (EOLS). This can be considered as Overvalued.
How profitable is EVOLUS INC (EOLS) stock?
EVOLUS INC (EOLS) has a profitability rating of 1 / 10.
What is the financial health of EVOLUS INC (EOLS) stock?
The financial health rating of EVOLUS INC (EOLS) is 2 / 10.
Can you provide the expected EPS growth for EOLS stock?
The Earnings per Share (EPS) of EVOLUS INC (EOLS) is expected to decline by -81.56% in the next year.